Targeting Tumor-Associated Antigens to the MHC Class I Presentation Pathway

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 7, Iss. 2, 2007-06 ,pp. : 99-109

Bentham Science Publishers

Access to resources Recommend Favorite

Oxazole- and Imidazole-Based Ser-Leu Dipeptide Mimetics in Potent Inhibitors of Antigen Presentation by MHC Class II DR Molecules

By Sarabu Ramakanth   Bolin David R.   Campbell Robert   Cooper Joel P.   Cox Donald   Gaizband Diana   Makofske Raymond   Nagy Zoltan   Olson Gary L.  

Drug Design and Discovery, Vol. 18, Iss. 1, 2002-03 ,pp. : 3-7

Taylor & Francis Ltd

Access to resources Recommend Favorite

Regulation of Antigen Presentation

By Kabcenell A.   Barton R.  

Inflammation Research, Vol. 47, Iss. 9, 1998-09 ,pp. : 357-358

Springer Publishing Company

Access to resources Recommend Favorite

Enhanced MHC class I and costimulatory molecules on B16F10 cells by Ganoderma lucidum polysaccharides

By Sun Li-Xin   Lin Zhi-Bin   Duan Xin-Suo   Lu Jie   Ge Zhi-Hua   Li Xue-Fei   Li Xue-Jun   Li Min   Xing En-Hong   Song You-Xin   Jia Jing   Li Wei-Dong  

Journal of Drug Targeting, Vol. 20, Iss. 7, 2012-08 ,pp. : 582-592

Informa Healthcare

Access to resources Recommend Favorite

MHC Class I TCR Engineered Anti-Tumor CD4 T Cells: Implications For Cancer Immunotherapy

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 4, 2009-01 ,pp. : 344-352

Bentham Science Publishers

Access to resources Recommend Favorite